Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
The Lancet. Gastroenterology & hepatology2025cited by 15position: middledoi
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure
Clinical Gastroenterology and Hepatology2024cited by 22position: middledoi